Table 2 Mean change in PETiT assessments among patients switched to lurasidone
| Â | Parameter | All patients* | Sedating | Non-sedating |
|---|---|---|---|---|
(N = 235) | (n = 83) | (n = 152) | ||
PETiT total score | Baseline (SD) | 35.0 (8.8) | 33.8 (8.6) | 35.7 (8.9) |
LOCF (SD) | 38.5 (9.2) | 36.5 (10.1) | 39.6 (8.5) | |
Mean change (SD) | 3.2 (8.5) | 2.7 (9.3) | 3.5 (8.1) | |
p-value | < 0.001 | 0.101 | < 0.001 | |
Adherence-related attitude domain score (6 items) | Baseline (SD) | 8.7 (2.1) | 8.4 (2.0) | 8.8 (2.1) |
LOCF (SD) | 9.4 (2.2) | 8.9 (2.6) | 9.7 (2.0) | |
Mean change (SD) | 0.7 (2.6) | 0.5 (2.8) | 0.8 (2.4) | |
p-value | 0.002 | 0.735 | < 0.001 | |
Psychosocial functioning domain score (24 items) | Baseline (SD) | 26.4 (7.7) | 25.4 (7.6) | 26.9 (7.8) |
LOCF (SD) | 29.1 (7.9) | 27.7 (8.6) | 29.9 (7.4) | |
Mean change (SD) | 2.5 (6.9) | 2.1 (7.4) | 2.7 (6.6) | |
p-value | < 0.001 | 0.074 | < 0.001 | |
Social functioning (4 items) | Baseline (SD) | 3.9 (1.4) | 3.6 (1.4) | 4.0 (1.4) |
LOCF (SD) | 4.0 (1.5) | 3.6 (1.5) | 4.2 (1.5) | |
Mean change (SD) | 0.1 (1.4) | -0.1 (1.5) | 0.1 (1.4) | |
p-value | 0.959 | 0.066 | 0.198 | |
Activity (7 items) | Baseline (SD) | 7.7 (2.8) | 7.6 (2.8) | 7.8 (2.8) |
LOCF (SD) | 8.5 (2.9) | 8.3 (3.0) | 8.6 (2.9) | |
Mean change (SD) | 0.7 (2.7) | 0.6 (2.8) | 0.8 (2.7) | |
p-value | 0.002 | 0.124 | 0.002 | |
Cognitive (7 items) | Baseline (SD) | 8.1 (2.8) | 7.8 (2.7) | 8.3 (2.8) |
LOCF (SD) | 9.1 (2.6) | 8.8 (2.9) | 9.3 (2.5) | |
Mean change (SD) | 0.9 (2.5) | 0.9 (2.8) | 0.9 (2.4) | |
p-value | < 0.001 | 0.006 | < 0.001 | |
Dysphoria (6 items) | Baseline (SD) | 6.7 (2.5) | 6.4 (2.3) | 6.8 (2.6) |
LOCF (SD) | 7.5 (2.4) | 7.0 (2.7) | 7.8 (2.1) | |
Mean change (SD) | 0.8 (2.3) | 0.7 (2.4) | 0.9 (2.2) | |
p-value | < 0.001 | 0.149 | < 0.001 |